RCTs | Ublituximab vs. Teriflunomide in relapsing multiple sclerosis.

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability. https://t.co/fpdtYhTNER pic.twitter.com/EPJEetSVdS

— NEJM (@NEJM) August 24, 2022